The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled ``Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis.'' The purpose of the public workshop is to discuss the clinical trial design challenges and future considerations for inhaled antibacterial products to treat cystic fibrosis (CF) and non-CF bronchiectasis.
Document
Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis; Public Workshop; Request for Comments
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled ``Development of Inhaled Antibacterial Drugs for Cystic Fibrosis a...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 26696
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis; Public Workshop; Request for Comments,” thefederalregister.org (June 8, 2018), https://thefederalregister.org/documents/2018-12341/development-of-inhaled-antibacterial-drugs-for-cystic-fibrosis-and-non-cystic-fibrosis-bronchiectasis-public-workshop-re.